Recent insights into C3 glomerulopathy

Nephrology Dialysis Transplantation

Volumn 28, Issue 7, 2013, Pages 1685-1693

  Barbour, Thomas D ^a   Pickering, Matthew C ^a   Terence Cook, H ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Complement; Dense deposit; Eculizumab; Glomerulonephritis; Kidney

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; ECULIZUMAB; MEMBRANE COFACTOR PROTEIN; NEPHRITIC FACTOR;

ANTIGEN BINDING; C3 GLOMERULONEPHRITIS; C3 GLOMERULOPATHY; CLINICAL FEATURE; COMPLEMENT FACTOR H GENE; COMPLEMENT FACTOR H RELATED PROTEIN 1 GENE; COMPLEMENT FACTOR H RELATED PROTEIN 3 GENE; COMPLEMENT FACTOR H RELATED PROTEIN 5 GENE; COMPLEMENT FACTOR H RELATED PROTEIN 5 NEPHROPATHY; COMPLEMENT FACTOR I GENE; COMPLEMENT SYSTEM; DENSE DEPOSIT DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; EXPERIMENTAL MODEL; GENE; GENE MUTATION; GENE STRUCTURE; GENETIC SCREENING; GENETIC VARIABILITY; GLOMERULONEPHRITIS; GLOMERULOPATHY; HISTOPATHOLOGY; HUMAN; KIDNEY DISEASE; MEMBRANE COFACTOR PROTEIN GENE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; SEQUENCE ANALYSIS;

COMPLEMENT; DENSE DEPOSIT; ECULIZUMAB; GLOMERULONEPHRITIS; KIDNEY;

ANIMALS; COMPLEMENT C3; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS;

EID: 84884520068     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs430     Document Type: Review

References (93)

1. Gunn WC. The variation in the amount of complement in the blood in some acute infectious diseases and its relation to the clinical features. J Pathol Bacteriol 1915; 19: 155-181
2. 1 glycoproteins of human serum. J Exp Med 1960; 111: 201
3. Seligmann M, Hanau C. Étude immuno-electrophorétique du sérum de malades atteits de lupus érythémateux disséminé. Rev Hémat (Paris) 1958; 13: 239
4. West CD, Northway JD, Davis NC. Serum Levels of Beta1C Globulin, a Complement Component, in the Nephritides, Lipoid Nephrosis, and Other Conditions. J Clin Invest 1964; 43: 1507-1517
5. West CD, McAdams AJ, McConville JM et al. Hypocomplementaemic and normocomplementaemic persistent (chronic) glomerulonephritis: clinical and pathologic characteristics. J Pediatr 1965; 67: 1089-9112
6. Lachmann PJ, Müller-Eberhard HJ, Kunkel HG et al. The localization of in vivo bound complement in tissue sections. J Exp Med 1962; 115: 63
7. Spitzer RE, Vallota EH, Forristal J et al. Serum C'3 lytic system in patients with glomerulonephritis. Science 1969; 164: 436-437
8. Berger J, Galle P. Altération singulière des membranes basales du rein. J Urol Nephrol (Paris) 1962; 68: 116-122
9. Mathew TH, Kincaid-Smith P. Membrano-proliferative glomerulonephritis (MPGN) with dense deposits in basement membrane. ASN Abstr 1971; 5: 51
10. Habib R, Gubler MC, Loirat C et al. Dense deposit disease: a variant of membranoproliferative glomerulonephritis. Kidney Int 1975; 7: 204-215
11. Marder HK, Coleman TH, Forristal J et al. An inherited defect in the C3 convertase, C3b,Bb, associated with glomerulonephritis. Kidney Int 1983; 23: 749-758
12. Levy M, Halbwachs-Mecarelli L, Gubler MC et al. H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int 1986; 30: 949-956
13. Lopez-Larrea C, Dieguez M, Enguix A et al. A familial deficiency of complement factor H. Biochem Soc Trans 1987; 15: 648-649
14. Linshaw MA, Stapleton FB, Cuppage FE et al. Hypocomplementemic glomerulonephritis in an infant and mother. Evidence for an abnormal form of C3. Am J Nephrol 1987; 7: 470-477
15. Fakhouri F, Frémeaux-Bacchi V, Noël LH et al. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 6: 494-499
16. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9: 729-740
17. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344: 1058-1066
18. Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344: 1140-1144
19. Lachmann PJ. The amplification loop of the complement pathways. Adv Immunol 2009; 104: 115-149
20. Rodriguez de Cordoba S, Lublin DM, Rubinstein P et al. Human genes for three complement components that regulate the activation of C3 are tightly linked. J Exp Med 1985; 161: 1189-1195
21. Smith RJ, Alexander J, Barlow PN et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007; 18: 2447-2456
22. Walker PD, Ferrario F, Joh K et al. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod Pathol 2007; 20: 605-616
23. Nasr SH, Valeri AM, Appel GB et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 2009; 4: 22-32
24. Andresdottir MB, Assmann KJ, Hoitsma AJ et al. Renal transplantation in patients with dense deposit disease: morphological characteristics of recurrent disease and clinical outcome. Nephrol Dial Transplant 1999; 14: 1723-1731
25. Sethi S, Gamez JD, Vrana JA et al. Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway. Kidney Int 2009; 75: 952-960
26. Cameron JS, Vick RM, Ogg CS et al. Plasma C3 and C4 concentrations in management of glomerulonephritis. Br Med J 1973; 3: 668-672
27. Williams DG, Scopes JW, Peters DK. Hypocomplementaemic membranoproliferative glomerulonephritis and nephrotic syndrome associated with partial lipodystrophy of the face and trunk. Proc R Soc Med 1972; 65: 591
28. Duvall-Young J, MacDonald MK, McKechnie NM. Fundus changes in (type II) mesangiocapillary glomerulonephritis simulating drusen: a histopathological report. Br J Ophthalmol 1989; 73: 297-302
29. Mullins RF, Aptsiauri N, Hageman GS. Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye 2001; 15(Pt 3): 390-395
30. Sepandj F, Trillo A. Dense deposit disease in association with monoclonal gammopathy of unknown significance. Nephrol Dial Transplant 1996; 11: 2309-2312
31. Sethi S, Sukov WR, Zhang Y et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis 2010; 56: 977-982
32. Lu DF, Moon M, Lanning LD et al. Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr Nephrol 2012; 27: 773-781.
33. Marks SD, Rees L. Spontaneous clinical improvement in dense deposit disease. Pediatr Nephrol 2000; 14: 322-324
34. Appel GB, Cook HT, Hageman G et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005; 16: 1392-1403
35. Servais A, Noël LH, Roumenina LT et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82: 454-464.
36. Angelo JR, Bell CS, Braun MC. Allograft failure in kidney transplant recipients with membranoproliferative glomerulonephritis. Am J Kidney Dis 2011; 57: 291-299
37. Sethi S, Fervenza FC, Zhang Y et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 2011; 6: 1009-1017
38. Servais A, Frémeaux-Bacchi V, Lequintrec M et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007; 44: 193-199
39. Sethi S, Zand L, Leung N et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol 2010; 5: 770-872
40. Bridoux F, Desport E, Frémeaux-Bacchi V et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol 2011; 6: 2165-2174
41. Hamburger J, Crosnier J, Noël LH. Recurrent glomerulonephritis after renal transplantation. Annu Rev Med 1978; 29: 67-72
42. Gale DP, Goicoechea de Jorge E, Cook HT et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010; 376: 794-801
43. Athanasiou Y, Voskarides K, Gale DP et al. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol 2011; 6: 1436-1446
44. Gale DP, Pickering MC. Regulating complement in the kidney: insights from CFHR5 nephropathy. Dis Model Mech 2011; 4: 721-726
45. Vernon KA, Gale DP, Goicoechea de Jorge E et al. Recurrence of complement factor H-related protein 5 nephropathy in a renal transplant. Am J Transplant 2011; 11: 152-155
46. Daha MR, Fearon DT, Austen KF. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol 1976; 116: 1-7
47. Cameron JS, Turner DR, Heaton J et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med 1983; 74: 175-192
48. Schwertz R, Rother U, Anders D et al. Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. Pediatr Allergy Immunol 2001; 12: 166-172
49. Walport MJ, Davies KA, Botto M et al. C3 nephritic factor and SLE: report of four cases and review of the literature. QJM 1994; 87: 609-615
50. Gewurz AT, Imherr SM, Strauss S et al. C3 nephritic factor and hypocomplementaemia in a clinically healthy individual. Clin Exp Immunol 1983; 54: 253-258
51. Strobel S, Zimmering M, Papp K et al. Anti-factor B autoantibody in dense deposit disease. Mol Immunol 2010; 47: 1476-1483
52. Chen Q, Müller D, Rudolph B et al. Combined C3b and factor B autoantibodies and MPGN type II. N Engl J Med 2011; 365: 2340-2342
53. Meri S, Koistinen V, Miettinen A et al. Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med 1992; 175: 939-950
54. Jokiranta TS, Solomon A, Pangburn MK et al. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol 1999; 163: 4590-4596
55. Dragon-Durey MA, Frémeaux-Bacchi V, Loirat C et al. Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 2004; 15: 787-795
56. Martínez-Barricarte R, Heurich M, Valdes-Cañedo F et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010; 120: 3702-3712
57. Licht C, Heinen S, Józsi M et al. Deletion of Lys224 in regulatory domain 4 of factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int 2006; 70: 42-50
58. Habbig S, Mihatsch MJ, Heinen S et al. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 2009; 75: 1230-1234
59. Wu J, Wu YQ, Ricklin D et al. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol 2009; 10: 728-733
60. Schejbel L, Schmidt IM, Kirchhoff M et al. Complement factor H deficiency and endocapillary glomerulonephritis due to paternal isodisomy and a novel factor H mutation. Genes Immun 2011; 12: 90-99
61. Servais A, Noël LH, Dragon-Durey MA et al. Heterogeneous pattern of renal disease associated with homozygous factor H deficiency. Hum Pathol 2011; 42: 1305-1311
62. Bomback AS, Smith RJ, Barile GR et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7: 748-756.
63. Montes T, Goicoechea de Jorge E, Ramos R et al. Genetic deficiency of complement factor H in a patient with age-related macular degeneration and membranoproliferative glomerulonephritis. Mol Immunol 2008; 45: 2897-2904
64. Leroy V, Frémeaux-Bacchi V, Peuchmaur M et al. Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation. Pediatr Nephrol 2011; 26: 419-424
65. Barbour TD, Johnson SA, Cohney SC et al. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant 2012; 27: 2673-2685.
66. Vernon KA, Pickering MC, Cook T. Experimental models of membranoproliferative glomerulonephritis, including dense deposit disease. Contrib Nephrol 2011; 169: 198-210
67. Abrera-Abeleda MA, Nishimura C, Frees K et al. Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol 2011; 22: 1551-1559
68. Abrera-Abeleda MA, Nishimura C, Smith JL et al. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 2006; 43: 582-589
69. Pickering MC, Goicoechea de Jorge E, Martínez-Barricarte R et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007; 204: 1249-1256
70. Heurich M, Martínez-Barricarte R, Francis NJ et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci USA 2011; 108: 8761-8766
71. Tortajada A, Pinto S, Martinez-Ara J et al. Complement factor H variants I890 and L1007 while commonly associated with atypical hemolytic uremic syndrome are polymorphisms with no functional significance. Kidney Int 2012; 81: 56-63
72. Dragon-Durey MA, Blanc C, Marliot F et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009; 46: 447-450
73. Józsi M, Licht C, Strobel S et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008; 111: 1512-1514
74. Zipfel PF, Edey M, Heinen S et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007; 3: e41
75. Smith RJ, Harris CL, Pickering MC. Dense deposit disease. Mol Immunol 2011; 48: 1604-1610
76. Gharavi AG, Kiryluk K, Choi M et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011; 43: 321-327
77. Hegasy GA, Manuelian T, Høgåsen K et al. The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: point mutations in the factor H coding sequence block protein secretion. Am J Pathol 2002; 161: 2027-2034
78. Høgåsen K, Jansen JH, Harboe M. Eradication of porcine factor H deficiency in Norway. Vet Rec 1997; 140: 392-395
79. Høgåsen K, Jansen JH, Mollnes TE et al. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 1995; 95: 1054-1061
80. Jansen JH, Høgåsen K, Grøndahl AM. Porcine membranoproliferative glomerulonephritis type II: an autosomal recessive deficiency of factor H. Vet Rec 1995; 137: 240-244
81. Jansen JH, Høgåsen K, Harboe M et al. In situ complement activation in porcine membranoproliferative glomerulonephritis type II. Kidney Int 1998; 53: 331-349
82. Jansen JH, Høgåsen K, Mollnes TE. Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease). Am J Pathol 1993; 143: 1356-1365
83. Pickering MC, Cook HT, Warren J et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002; 31: 424-428
84. Pickering MC, Warren J, Rose KL et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci USA 2006; 103: 9649-9654
85. Alexander JJ, Wang Y, Chang A et al. Mouse podocyte complement factor H: the functional analog to human complement receptor 1. J Am Soc Nephrol 2007; 18: 1157-1166
86. Rose KL, Paixão-Cavalcante D, Fish J et al. Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest 2008; 118: 608-618
87. Paixão-Cavalcante D, Hanson S, Botto M et al. Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase. Mol Immunol 2009; 46: 1942-1950
88. Fakhouri F, Goicoechea de Jorge E, Brune F et al. Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int 2010; 78: 279-286
89. Droz D, Nabarra B, Noël LH et al. Recurrence of dense deposits in transplanted kidneys: I. Sequential survey of the lesions. Kidney Int 1979; 15: 386-395
90. Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med 2012; 366: 1161-1163
91. Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med 2012; 366: 1163-1165
92. McCaughan JA, O'Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 2012; 12: 1046-1051.
93. West CD, Witte DP, McAdams AJ. Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2. Am J Kidney Dis 2001; 37: 1120-1130